Which RNA technologies currently hold the greatest promise to drive development?
Quick: This will require quality control, diagnostics, and therapeutic support of extraordinarily high quality. From my perspective, sequencing methods, assays for delivery systems qualification, flow cytometry, and functional bioassays show great potential.
What is your current research focus in RNA technologies?
Quick: As Spokesperson of the Board of the Life Science Research Department of the Association of the Diagnostics Industry (VDGH), which has been supporting the MEDICA LABMED Forum for years, I speak for all LSR member companies that are working to advance these technologies. I also represent the member company Promega GmbH, which I started building in 1996. Within this context, Promega focuses on functional bioassays and on STR analysis, which is known as a mainstay of forensics.
What do you expect from the lectures on RNA technologies at the MEDICA LABMED FORUM?
Quick: These lectures impart basic knowledge, discuss the latest progress, and point out exciting opportunities. They essentially “whet your appetite” for a deeper understanding and appreciation of the subject. They also create excitement over the duality shown to the previous paths of gene and cell therapy, which will be addressed by subsequent lectures.
Why do you think MEDICA is the right platform to address this topic?
Quick: The trade fair showcases solutions and products that are available or will be available shortly. There is a need for guidance and for building a pathway to the future as industry and academia are eager to understand and learn everything about the trends - and are ready to connect and seize opportunities together. That’s why on Thursday, November 17th, we get the chance to meet speakers from both industry and basic research at the MEDICA LABMED FORUM.